Elranatamab (Elrexfio) is a BCMA×CD3 bispecific antibody that redirects T cells to BCMA-expressing myeloma cells to mediate cytotoxicity.
Elranatamab is a bispecific antibody that simultaneously binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells to tumor cells to trigger T-cell activation and cytotoxic killing of BCMA-expressing myeloma cells.
YES
DIRECT
Elranatamab bridges CD3 on T cells to BCMA on target cells, activating T cells to kill BCMA+ cells via perforin/granzyme-mediated cytotoxicity and apoptosis.
Elranatamab (Elrexfio) is a BCMA×CD3 bispecific antibody that redirects T cells to BCMA-expressing myeloma cells to mediate cytotoxicity.
Elranatamab is a bispecific antibody that simultaneously binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells to tumor cells to trigger T-cell activation and cytotoxic killing of BCMA-expressing myeloma cells.
NO
INDIRECT
Elranatamab binds CD3ε on T cells to activate and redirect them; the activated T cells kill BCMA-expressing myeloma cells (perforin/granzyme), not the CD3+ T cells themselves.
An off-the-shelf, full-length bispecific T-cell–engaging antibody that binds BCMA on malignant plasma cells and CD3 on T cells to redirect cytotoxic T cells against multiple myeloma cells.
Bispecific humanized monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, cross-linking them to form an immune synapse, activate T cells, and redirect cytotoxic T-cell killing of BCMA-expressing myeloma cells.
YES
DIRECT
Bispecific BCMA×CD3 engagement cross-links T cells to BCMA-expressing cells, forming an immune synapse and triggering perforin/granzyme-mediated T-cell cytotoxicity leading to apoptosis.
An off-the-shelf, full-length bispecific T-cell–engaging antibody that binds BCMA on malignant plasma cells and CD3 on T cells to redirect cytotoxic T cells against multiple myeloma cells.
Bispecific humanized monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, cross-linking them to form an immune synapse, activate T cells, and redirect cytotoxic T-cell killing of BCMA-expressing myeloma cells.
NO
INDIRECT
Teclistamab binds CD3 on T cells to activate and redirect them to kill BCMA-expressing myeloma cells; CD3+ T cells are not the cells killed.
A bispecific T-cell–redirecting antibody that binds GPRC5D on myeloma/plasma cells and CD3 on T cells, inducing T-cell–mediated cytotoxicity.
Bispecific humanized antibody that binds CD3 on T cells and GPRC5D on myeloma cells, cross-linking and activating T cells to mediate cytotoxic killing of GPRC5D-expressing tumor cells.
YES
DIRECT
Talquetamab links CD3 on T cells to GPRC5D on target cells, activating cytotoxic T cells to kill GPRC5D+ cells via perforin/granzyme–mediated apoptosis.